Stock SIOX SIO GENE THERAPIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Sio Gene Therapies Inc. Stock Nasdaq

Equities

SIOX

US8293991043

Delayed Nasdaq
Other stock markets
 03:58:58 2024-02-07 pm EST 		5-day change 1st Jan Change
0.478 USD +1.70% Intraday chart for Sio Gene Therapies Inc. +22.88% +29.19%
2023 Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index CI
2023 Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index CI

Chart Sio Gene Therapies Inc.

Dynamic Chart

Latest news about Sio Gene Therapies Inc.

Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index CI
Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index CI
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours MT
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Sio Gene Therapies Inc.(NasdaqGS:SIOX) dropped from S&P Global BMI Index CI
Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Top Premarket Decliners MT
HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy MT
Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80 MT
Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value CI
Sio Gene Therapies Receives Nasdaq Listing Noncompliance Notice Over Minimum Closing Price MT
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
More news

Analyst Recommendations on Sio Gene Therapies Inc.

HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy MT
Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80 MT
Cantor Adjusts Sio Gene Therapies Price Target to $3 From $8, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Sio Gene Therapies to $7 From $10, Reiterates Buy Rating MT
SVB Leerink Downgrades Sio Gene Therapies to Market Perform From Outperform, Adjusts Price Target to $1 From $6 MT
More recommendations

Press releases Sio Gene Therapies Inc.

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share GL
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share AQ
SIO GENE THERAPIES INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K PU
SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) AQ
More press releases

Managers and Directors - Sio Gene Therapies Inc.

Managers TitleAgeSince
David Nassif CEO
 Chief Executive Officer 70 19-06-30
Raquel Crystal COO
 Chief Operating Officer - -
Members of the board TitleAgeSince
David Nassif CEO
 Chief Executive Officer 70 19-06-30
More insiders

Company Profile

Sio Gene Therapies Inc. was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The Company has not generated any revenue.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. SIOX Stock
  4. SIOX Stock